Novel Strategies in the Prevention/Treatment of Colorectal Cancer

Guest Editors:

Prof. Dr. William H. Gmeiner
Department of Cancer Biology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA

Prof. Dr. Dan A. Dixon
Department of Molecular Biosciences, University of Kansas, Lawrence, KS 66045, USA

Prof. Dr. Margie Lee Clapper
Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA

Deadline for manuscript submissions:
30 November 2024

Message from the Guest Editors

The signaling pathways dysregulated during canonical CRC initiation and progression are potential targets for both chemoprevention and cancer treatment. However, the Wnt, P53, and TGF-b pathways have not been fully exploited for drug development to either reduce CRC incidence or improve treatment, in part because of their key role in normal tissue homeostasis and the difficulty in developing drugs for these targets. Chemoprevention of CRC for high-risk individuals (e.g., Lynch syndrome) is still under development, albeit with promising pre-clinical results targeting mediators of inflammation, such as COX-2, and other targets such as HMG-CoA reductase. Adjuvant chemotherapy for locally advanced CRC uses fluoropyrimidine combinations such as FOLFOX to target TS and DNA damage while treatment of metastatic disease may use these same combinations or drugs or antibodies to target EGFR, VEGF, and more recently BRAF and KRAS.

The current Special Issue will focus on original research articles and comprehensive reviews illuminating the most recent advances in understanding the molecular pathways of CRC initiation and progression that are amenable to therapeutic intervention.

Special Issue

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us